{"entity":{"id":"pacific-2","kind":"trial","name":"PACIFIC-2","aka":[],"tldr":"PACIFIC-2 asked whether starting durvalumab during chemoradiotherapy, rather than after it, would help people with stage III lung cancer; it did not, so the sequence established by the original PACIFIC trial stands.","summary":"PACIFIC established durvalumab given after chemoradiotherapy as the standard for unresectable stage III non-small-cell lung cancer. PACIFIC-2 tested the more aggressive schedule of starting durvalumab at the same time as platinum-based chemoradiotherapy and continuing it afterwards, against placebo, in 328 patients. The primary endpoint was progression-free survival.\n\nThe trial did not show a statistically significant improvement in progression-free survival, and more patients in the durvalumab arm stopped treatment early for adverse events. Consolidation after chemoradiotherapy therefore remains the way durvalumab is used in this setting.","status":"negative","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT03519971","url":"https://clinicaltrials.gov/study/NCT03519971"}],"tags":["subtype-trials"],"related":[],"cancers":["stage-iii-unresectable-nsclc","nsclc","lung-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["durvalumab","cisplatin","carboplatin"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jeffrey-bradley"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03519971","phase":"3","setting":"Unresectable stage III non-small-cell lung cancer: durvalumab or placebo given together with platinum chemoradiotherapy and continued afterwards","sponsor":"AstraZeneca","result":"Concurrent durvalumab with chemoradiotherapy did not significantly improve progression-free survival over chemoradiotherapy alone.","started":"2018-03-29","startedType":"actual","yearReported":2024,"enrolled":328,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival (registry results)","primary":true,"unit":"months","arms":[{"name":"Durvalumab + concurrent chemoradiotherapy","value":13.8,"note":"95% CI 9.5 to 16.9"},{"name":"Placebo + concurrent chemoradiotherapy","value":9.4,"note":"95% CI 7.5 to 16.6"}],"hr":0.85,"ci":[0.647,1.123],"p":"0.247","source":"https://clinicaltrials.gov/study/NCT03519971?tab=results"}]},"route":"/trials/pacific-2/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"person":[{"id":"jeffrey-bradley","kind":"person","name":"Jeffrey D. Bradley","route":"/people/jeffrey-bradley/"}],"term":[{"id":"lung-failed-programmes","kind":"term","name":"Lung cancer: the failed and stopped programmes, and why","route":"/terms/lung-failed-programmes/"}],"trial":[{"id":"gemstone-301","kind":"trial","name":"GEMSTONE-301","route":"/trials/gemstone-301/"}]}}